Skip to main content

Pharma News

 

Clinical courses

 

Clinical research courses

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Scripps Research scientists uncover new molecular drivers of Alzheimer’s

    According to the US Centers for Disease Control and Prevention, at least 5.8 million Americans are currently living with Alzheimer’s disease, which is the most common form of dementia. There is no cure for Alzheimer’s, in part because scientists do not yet have a full understanding of what causes the disease. But a new study from Scripps Research is shedding light on the molecular drivers that could contribute to Alzheimer’s progression.

  • New advances in cancer viral immunotherapy

    Vaccinia viruses are therapeutic tools with different biomedical applications depending on the susceptibility characteristics. For example, the strain called MVA (modified vaccinia Ankara), which is unable to replicate in mammalian cells, triggers a potent immune system response and is used to develop vaccines against COVID-19 or AIDS. In contrast, other strains such as Western Reserve (WR) or Copenhagen (Cop), which replicate efficiently in tumour cells, are used to develop cancer treatments.

  • Nitrosamine Advance Workshop 2024 A Comprehensive Post-Show Review

    Nitrosamine Advance Workshop 2024, conducted on May 9th and 10th at Radisson Blu Mumbai International Airport, has emerged as a watershed moment in the pharma industry boosting collaboration and innovation in the detection of the Nitrosamine landscape.

  • Advance DoE Workshop 2024 : A Testament to the Power of Collaboration, education, and innovation

    An exclusive Advance DoE Workshop 2024 hosted by Eminence Business Media, concluded with resounding success, inspiring participants with valuable insights to enhance their experimental design and optimization skills.

  • A Trial HIV Vaccine Triggered Elusive and Essential Antibodies in Humans

    An HIV vaccine candidate developed at the Duke Human Vaccine Institute triggered low levels of an elusive type of broadly neutralizing HIV antibodies among a small group of people enrolled in a 2019 clinical trial.

    The finding, reported May 17 in the journal Cell, not only provides proof that a vaccine can elicit these antibodies to fight diverse strains of HIV, but that it can also initiate the process within weeks, setting in motion an essential immune response.

  • Study Paves the Way for an Active Agent Against Hepatitis E
    At present, there is no specific active substance against hepatitis E. As the disease kills 70,000 people every year, researchers are actively searching for one. The team from the Department of Molecular and Medical Virology at Ruhr University Bochum, Germany, may have found what they’re looking for.
  • Lupin Achieves Significant Milestone with ISO 14001 and ISO 45001 Certification Across All its Indian Manufacturing Sites, R&D Center and Corporate Office

    Global pharma major Lupin Limited announced that all 12 of its manufacturing sites, its R&D Center and corporate office in India have successfully completed rigorous audits and been certified by DNV for ISO 14001 Environment Management Systems (EMS), and ISO 45001 Occupational Health and Safety Management System (OHSMS). This achievement marks a significant milestone in acknowledging Lupin’s commitment to safe and sustainable operations.

  • WHO prequalifies new dengue vaccine
    WHO recommends the use of TAK-003 in children aged 6–16 years in settings with high dengue burden and transmission intensity. The vaccine should be administered in a 2-dose schedule with a 3-month interval between doses.
  • Merck Provides Update on Phase 3 KeyVibe-010 Trial Evaluating

    Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the discontinuation of the vibostolimab and pembrolizumab coformulation arm of the Phase 3 KeyVibe-010 trial. The trial is evaluating the investigational coformulation of vibostolimab, an anti-TIGIT antibody, and pembrolizumab (KEYTRUDA®), Merck’s anti-PD-1 therapy, compared to KEYTRUDA alone, as adjuvant treatment for patients with resected high-risk melanoma (Stage IIB-IV). 

  • Plant Virus Treatment Shows Promise in Fighting Metastatic Cancers in Mice

    An experimental treatment made from a plant virus is effective at protecting against a broad range of metastatic cancers in mice, shows a new study from the University of California San Diego.

Subscribe to Pharma News